NCT02720081View on ClinicalTrials.gov

Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)

PHASE2CompletedINTERVENTIONAL

Enrollment

142

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

August 16, 2017

Study Completion Date

September 6, 2017

Conditions

Asthma

Interventions

DRUG

MK-1029 150 mg

150 mg tablet administered orally, once a day (QD), at bedtime

DRUG

MK-1029 Matching-image Placebo

Matching-image placebo tablet administered orally, QD, at bedtime

DRUG

Montelukast 10 mg

10 mg tablet administered orally, QD, at bedtime

DRUG

Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation

1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02720081 - Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015) | Biotech Hunter | Biotech Hunter